利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.042 秒)

    METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    11.
    发明公开
    METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION 审中-公开
    治疗与MASP-2依赖性补体活化有关的病症的方法

    公开(公告)号：EP3287142A1

    公开(公告)日：2018-02-28

    申请号：EP17191208.2

    申请日：2012-04-06

    申请人： University of Leicester ,  Omeros Corporation

    发明人： DEMOPULOS, Gregory A. ,  DUDLER, Tom ,  SCHWAEBLE, Hans-Wilhelm

    IPC分类号： A61K39/395 ,  C12N15/11 ,  C07K16/40

    CPC分类号： C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

    摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

    摘要翻译： 一方面，本发明提供了抑制活体中MASP-2依赖性补体活化作用的方法。 该方法包括向有需要的受试者施用有效抑制MASP-2依赖性补体激活的量的MASP-2抑制剂的步骤。 在一些实施方案中，MASP-2抑制剂抑制与MASP-2介导的替代补体途径活化相关的细胞损伤，同时使免疫系统的经典（C1q依赖性）途径组分保持完整。 另一方面，本发明提供了用于抑制凝集素依赖性补体活化作用的组合物，其包含治疗有效量的MASP-2抑制剂和药学上可接受的载体。

    METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    18.
    发明公开
    METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION 审中-公开

    公开(公告)号：EP3964233A1

    公开(公告)日：2022-03-09

    申请号：EP21188935.7

    申请日：2012-04-06

    申请人： University of Leicester ,  Omeros Corporation

    发明人： DEMOPULOS, Gregory A. ,  DUDLER, Tom ,  SCHWAEBLE, Hans-Wilhelm

    IPC分类号： A61K39/395 ,  C12N15/11 ,  C07K16/40

    摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

    METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION
    20.
    发明公开
    METHODS FOR TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITING MASP-2 DEPENDENT COMPLEMENT ACTIVATION 审中-公开
    一种用于治疗传播性血管内凝血BY抑制MASP-2依赖的补

    公开(公告)号：EP3150635A2

    公开(公告)日：2017-04-05

    申请号：EP16199359.7

    申请日：2010-10-15

    申请人： Omeros Corporation ,  UNIVERSITY OF LEICESTER

    发明人： SCHWAEBLE, Hans-Wilhelm ,  DUDLER, Thomas A ,  TEDFORD, Clark E ,  PARENT, James B ,  DEMOPULOS, Gregory A

    IPC分类号： C07K16/40

    CPC分类号： C07K16/40 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92 ,  C12Y304/21104

    摘要： In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. In one embodiment, the invention provides methods of treating a subject suffering from a complement mediated coagulation disorder, such as disseminated intravascular coagulation. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (Clq-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

    摘要翻译： 在一个方面，本发明提供的抑制在活的受试者MASP-2依赖性补体活化的影响的方法。 在一个，实施例本发明提供治疗由补体介导凝血障碍，：患有如弥散性血管内凝血的方法。 方法包括施用的步骤，以在需要其的受试者，在一个有效MASP-2抑制剂的量来抑制MASP-2依赖性补体活化。 在一些实施方案中，MASP-2抑制剂抑制与MASP-2介导的补体旁路途径活化相关的细胞损伤，同时使经典（C1q的依赖性）途径免疫系统的组成部分保持完整。 在另一个方面，本发明提供用于抑制凝集素依赖性补体激活的作用，其包含治疗有效量的MASP-2抑制剂和药学上可接受的载体的组合物。